Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
SURG-073 A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-based, Protocol-driven Management in Patients Undergoing Elective Major Cancer Surgery III Not Applicable
1VIT14039 IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) III
PV-10-MM-31 PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma Without Distant Metastases III Chemotherapy temozolomide; dacarbazine; PV-10
UPCC-06612 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence III Signal Transduction Inhibitor vemurafenib
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
TS001RSUM An Open-label, Single Institution Phase II Study Using Radioactive yttrium90 Microsphere (SIR-Spheres® Microspheres) in Uveal Melanoma Patients With Hepatic Metastasis II Radiation Therapy Not Applicable
ML28897 My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor trastuzumab; erlotinib; pertuzumab; vemurafenib; vismodegib
J1365 Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor pembrolizumab
12-048 A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma II Immunotherapy (Vaccine), Signal Transduction Inhibitor dasatinib; Dendritic Cell Vaccine
13P.377 A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma II Signal Transduction Inhibitor sunitinib; valproic acid (VPA)
116521 An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain II Signal Transduction Inhibitor trametinib; dabrafenib
10-096 A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors I / II Chemotherapy, Signal Transduction Inhibitor etoposide; vorinostat
C32496/1105 An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2 I / II Signal Transduction Inhibitor
12-107 Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma I / II Immunotherapy, Signal Transduction Inhibitor interferon alfa-2a; vemurafenib
CD-ON-MEDI4736-1108 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors I / II Immunotherapy (Monoclonal Antibody)
INCB 24360-202 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors (Phase 1) Followed by a Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Advanced NSCLC (Phase 2)(INCB 24360-202 / MK-3475-037 / KEYNOTE-037) I / II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor INCB024360; pembrolizumab
UPCC-06611 RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma I / II Radiation Therapy, Immunotherapy (Monoclonal Antibody) ipilimumab
UPCC 02614 The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma I / II Signal Transduction Inhibitor trametinib
14P.524 An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma and Non-Small Cell Lung Cancer I Immunotherapy (Monoclonal Antibody) pembrolizumab
C28001 An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma I Signal Transduction Inhibitor
UPCI-10-115 An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I Chemotherapy, PARP Inhibitor carboplatin; paclitaxel; veliparib
09-051 A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases I Radiation Therapy Not Applicable
09-021 A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients I Immunotherapy Not Applicable
OER-RT-042 Phase I Study of Pulsed Low Dose Rate Reirradiation Delivered With 3DCRT/IMRT I Radiation Therapy Not Applicable
120066 Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor 5-fluoro-2-deoxycytidine; tetrahydrouridine
12P.314 Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases I Radiation Therapy, Immunotherapy (Monoclonal Antibody) ipilimumab
11-091 PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES I Radiation Therapy Not Applicable
13-105 Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma I Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor peginterferon alfa-2b; pembrolizumab
UPCC 08913 A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green I Imaging Procedure Indocyanine Green
UPCC 01611 Phase I Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells Against Cancer-testis Antigens in Metastatic Melanoma I Immunotherapy Not Applicable
UPCC 01615 A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma I Immunotherapy pembrolizumab
UPCC 27914 A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer I Biological Therapy, Chemotherapy, Hormonal Therapy letrozole; midazolam;
UPCC-06613 A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma I Signal Transduction Inhibitor vemurafenib; hydroxychloroquine
CD-ON-MEDI3617-1043 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617, a Fully Human Monoclonal Antibody Directed Against ANG2, in Adult Subjects With Advanced Solid Tumors I Immunotherapy (Monoclonal Antibody)
110060 A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction I Signal Transduction Inhibitor belinostat
IMGN853-0401 A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors I Immunotherapy (Monoclonal Antibody)
C28002 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies I Chemotherapy, Signal Transduction Inhibitor paclitaxel; alisertib; ;
PV-10-LC-01 A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Recurrent Hepatocellular Carcinoma I Chemotherapy PV-10
08-067 Pilot Analysis of the Effects of IFN a2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes 0 Immunotherapy interferon alfa-2b
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy Not Applicable
UPCI 14-102 Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b in Patients With Locally/Regionally Advanced/Recurrent Melanoma: Safety, Efficacy and Biomarker Study Not Specified Immunotherapy (Monoclonal Antibody) pegylated interferon alfa-2a; pembrolizumab
11-063 Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-alpha2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study Not Specified Immunotherapy (Monoclonal Antibody), Immunotherapy interferon alfa-2b; ipilimumab
14D.272 Use of a Brief Mindful Meditation Practice in Adult Cancer Patients Receiving Radiation Therapy Not Specified Not Applicable
STUDY00000378 The Value of Integrating Visual Arts (VIVA): Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing Not Specified Not Applicable
PRO00000367 A Low-Carbohydrate Diet for Advanced or Metastatic Cancer Not Specified Other Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood or Tissue Collection Not Applicable
CA209-218 Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma Not Specified Immunotherapy (Monoclonal Antibody) nivolumab; ipilimumab
NCT01295658 Cancer Experience Registry Not Specified Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Penn Non-Treatment Trials trials

Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Phase 1: Solid Tumor Trials trials

Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.